Skip to main content
Journal cover image

Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.

Publication ,  Journal Article
Wechsler, RT; Radtke, RA; Smith, M; Vossler, DG; Strom, L; Trinka, E; Cheng, H; Grinnell, T; Blum, D; Vieira, M; Moreira, J; Rocha, F
Published in: Epilepsia
July 2019

OBJECTIVE: To examine the frequency of hyponatremia and potentially related symptoms in clinical trials of eslicarbazepine acetate (ESL) in adults with focal- (partial-) onset seizures. METHODS: This post hoc, exploratory analysis included data from three controlled phase 3 trials of adjunctive ESL (400-1200 mg once daily), two phase 3 trials of ESL monotherapy (1200-1600 mg once daily), and their open-label extension studies. Exploratory endpoints included clinical laboratory measurements of serum sodium concentrations ([Na+ ]), incidences of hyponatremia-related treatment-emergent adverse events (TEAEs), and incidences of TEAEs that are potential symptoms of hyponatremia. RESULTS: The controlled trials of adjunctive ESL and ESL monotherapy included 1447 (placebo, n = 426; ESL, n = 1021) and 365 (ESL, n = 365) patients, respectively; 639 and 274 patients continued onto uncontrolled, open-label extensions. In the controlled and uncontrolled trials ≤3.3% of patients taking ESL had a minimum postdose [Na+ ] measurement ≤125 mEq/L, <9% had a >10 mEq/L decrease in [Na+ ] from baseline, <6% had a hyponatremia-related TEAE, and <2% discontinued the controlled trials due to a hyponatremia-related TEAE. Hyponatremia appeared to be more frequent in the monotherapy (vs adjunctive therapy) trials; in the controlled trials of adjunctive ESL and ESL monotherapy, incidence generally increased with increasing ESL dose. The majority of patients with an investigator-reported TEAE of "hyponatremia" or "blood sodium decreased" did not have a corresponding laboratory [Na+ ] measurement ≤125 mEq/L. Some symptoms potentially related to hyponatremia (including nausea and vomiting) were more frequent in patients with a minimum postdose [Na+ ] measurement ≤125 mEq/L. SIGNIFICANCE: Reductions in serum sodium concentrations and hyponatremia-related TEAEs occurred in a small number of patients taking ESL. Suspected hyponatremia should be confirmed and monitored via [Na+ ] measurements.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Epilepsia

DOI

EISSN

1528-1167

Publication Date

July 2019

Volume

60

Issue

7

Start / End Page

1341 / 1352

Location

United States

Related Subject Headings

  • Young Adult
  • Sodium
  • Neurology & Neurosurgery
  • Middle Aged
  • Hyponatremia
  • Humans
  • Epilepsy
  • Epilepsies, Partial
  • Dibenzazepines
  • Anticonvulsants
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wechsler, R. T., Radtke, R. A., Smith, M., Vossler, D. G., Strom, L., Trinka, E., … Rocha, F. (2019). Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy. Epilepsia, 60(7), 1341–1352. https://doi.org/10.1111/epi.16069
Wechsler, Robert T., Rodney A. Radtke, Michael Smith, David G. Vossler, Laura Strom, Eugen Trinka, Hailong Cheng, et al. “Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.Epilepsia 60, no. 7 (July 2019): 1341–52. https://doi.org/10.1111/epi.16069.
Wechsler RT, Radtke RA, Smith M, Vossler DG, Strom L, Trinka E, et al. Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy. Epilepsia. 2019 Jul;60(7):1341–52.
Wechsler, Robert T., et al. “Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy.Epilepsia, vol. 60, no. 7, July 2019, pp. 1341–52. Pubmed, doi:10.1111/epi.16069.
Wechsler RT, Radtke RA, Smith M, Vossler DG, Strom L, Trinka E, Cheng H, Grinnell T, Blum D, Vieira M, Moreira J, Rocha F. Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy. Epilepsia. 2019 Jul;60(7):1341–1352.
Journal cover image

Published In

Epilepsia

DOI

EISSN

1528-1167

Publication Date

July 2019

Volume

60

Issue

7

Start / End Page

1341 / 1352

Location

United States

Related Subject Headings

  • Young Adult
  • Sodium
  • Neurology & Neurosurgery
  • Middle Aged
  • Hyponatremia
  • Humans
  • Epilepsy
  • Epilepsies, Partial
  • Dibenzazepines
  • Anticonvulsants